CA2396796A1 - Stabilized medicinal aerosol particulate formulations - Google Patents
Stabilized medicinal aerosol particulate formulations Download PDFInfo
- Publication number
- CA2396796A1 CA2396796A1 CA002396796A CA2396796A CA2396796A1 CA 2396796 A1 CA2396796 A1 CA 2396796A1 CA 002396796 A CA002396796 A CA 002396796A CA 2396796 A CA2396796 A CA 2396796A CA 2396796 A1 CA2396796 A1 CA 2396796A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- group
- mixture
- foregoing
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A medicinal formulation is disclosed. The formulation comprises: a therapeut ic amount of a protein or peptide medicament, a fluid for containing said medicament having a molecular size ranging from 1 K Dalton to about 150 K Daltons, a fluid carrier for containing the medicament, and a stabilizer selected from an amino acid, a derivative thereof or a mixture of the foregoing.
Claims (18)
1. A medicinal formulation, which comprises:
(a) a therapeutically effective amount of a protein or peptide medicament having a molecular size ranging from about 1K Dalton to about 150 K
Daltons;
(b) a fluid carrier for containing said medicament; and (c) a stabilizer selected from an amino acid, a derivative thereof, or a mixture of the foregoing.
(a) a therapeutically effective amount of a protein or peptide medicament having a molecular size ranging from about 1K Dalton to about 150 K
Daltons;
(b) a fluid carrier for containing said medicament; and (c) a stabilizer selected from an amino acid, a derivative thereof, or a mixture of the foregoing.
2. The formulation as defined in claim 1 wherein said medicament is selected from the group consisting of an insulin, an insulin analog, an amylin, an immunomodulating protein, an interleukin, an interferon, an erythropoietin, a heparin, a thrombolytic, an antitrypsin, an anti-protease, a hormone, a growth factor, an enzyme, a nucleic acid, an immunoglobulin, an antibiotic, an antiinfective, a calcitonin, a hematopoietic factor, a vaccine, a vasoactive peptide, an antisense agent, an oligonucleotide, DNase, a cyclosporin, ribavirin or a mixture of any of the foregoing medicaments.
3. The formulation as defined in claim 1 wherein said medicament is selected from the group consisting of an insulin, an insulin analog, an amylin, glucagon, LH-RH, deltirex, leuprolide, gosorelin, nafarelin, octreotide, somatostatin, a calcitonin, parathyroid hormone, TRH, growth hormone-releasing hormone, G-CSF, G-SF, a cytokine, rhDNAse, a heparin, an antibiotic, albumin, ovalbumin, aminloride, DDAVP, VIP, a cyclosporin, an erythropoietin, an interferon, IgG, IgE, IgM, IgA, IgD, an interleukin, IRAP, papain, peroxidase, serratio peptidase, catalase, .alpha.-1-antitrypsin, a gene; a vector, an amiloride, a rhDNAse, an oligonucleotide, ribavirin or a mixture of any of the foregoing medicaments.
4. The formulation as defined in claim 1, wherein said stabilizer is selected from the group consisting of the twenty existing amino acids, any mixture thereof, and any derivative of the foregoing.
5. The formulation as defined in claim 1 wherein said stabilizer is selected from the group consisting of (1) a di-peptide selected from the group consisting of a salt and an ester of oxidized and unoxidized L-cysteinylglycine, gamma-L-glutamyl-L-cysteine, N-acetyl-L-cysteine-glycine; (2) a conjugated, unconjugated or polymeric form of L-Gly-L-Glu and L-Val-L-Thr; (3) L-aspartyl-L-phenylalanine; (4) a muramyl dipeptide; (5) a nutrient selected from the group consisting of L-tyrosyl-L-tyrosine, L-alanyl-L-tyrosine, L-arginyl-L-tyrosine, L-tyrosyl-L-arginine, N-Cbz-L-Leu-L-Leu-OCH and salts or esters of the foregoing;
(6) glycyl-glycine; (7) N-acetyl-L-aspartate-L-glutamate; (NAAG); (8) a tripeptide selected from the group consisting of an oxidized and an unoxidized form of gamma-L-glutamyl-L-cysteinylglycine or a muramyl tripeptide and (9) a mixture of any of the foregoing stabilizers.
(6) glycyl-glycine; (7) N-acetyl-L-aspartate-L-glutamate; (NAAG); (8) a tripeptide selected from the group consisting of an oxidized and an unoxidized form of gamma-L-glutamyl-L-cysteinylglycine or a muramyl tripeptide and (9) a mixture of any of the foregoing stabilizers.
6. The formulation as defined in claim 1 wherein said fluid carrier is a propellant selected form the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.
7. The formulation as defined in claim 1 wherein said fluid carrier is a hydrocarbon propellant selected from the group consisting of n-butane, propane, isopentane or a mixture thereof.
8. The formulation as defined in claim 1 which further includes a cosolvent.
9. The formulation as defined in claim 8 wherein said cosolvent comprises ethanol.
10. The formulation as defined in claim 1 wherein said stabilizer is present in an amount effective to prevent settling, creaming or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.
11. The formulation as defined in claim 10 wherein said stabilizer is present in an amount ranging from about 0.001 parts per million to about 200,000 parts per million of the total weight of the formulation.
12. A method of preparing a stable medicinal aerosol formulation according to claim 1, which comprises:
(a) combining (i) said medicament in an amount sufficient to provide a plurality of therapeutically effective doses, (ii) said fluid carrier in an amount sufficient to propel a plurality of said therapeutically effective doses; and (iii) said stabilizer in an amount effective to stabilize the formulation; and (b) dispersing components (i), (ii) and (iii).
(a) combining (i) said medicament in an amount sufficient to provide a plurality of therapeutically effective doses, (ii) said fluid carrier in an amount sufficient to propel a plurality of said therapeutically effective doses; and (iii) said stabilizer in an amount effective to stabilize the formulation; and (b) dispersing components (i), (ii) and (iii).
13. The method as defined in claim 12 wherein the medicinal aerosol formulation further comprises combining in step (a) a cosolvent and in step (b) dispersing components (i), (ii), (iii) with said cosolvent.
14. A method of treating in a human or an animal a condition capable of treatment by oral or nasal inhalation, which comprises, administering a formulation according to claim 1 to said human or animal by oral or nasal inhalation.
15. A formulation according to claim 1 in an aerosol canister equipped with a metered dose valve.
16. A method of stabilizing a suspension aerosol formulation comprising a propellant and a protein or peptide medicament, which comprises, incorporating into the formulation a stabilizer selected from the group consisting of a suitable amino acid, a derivative thereof, or any mixture of the foregoing, in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.
17. A metered dose inhaler containing a medicinal aerosol formulation, the formulation comprising:
(a) a protein or peptide medicament in a therapeutically effective amount;
(b) a propellant; and (c) a suitable stabilizer selected from an amino acid, an amino acid derivative, or a mixture of the foregoing, present in an amount sufficient to stabilize the formulation to prevent settling, creaming or flocculation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.
(a) a protein or peptide medicament in a therapeutically effective amount;
(b) a propellant; and (c) a suitable stabilizer selected from an amino acid, an amino acid derivative, or a mixture of the foregoing, present in an amount sufficient to stabilize the formulation to prevent settling, creaming or flocculation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.
18. The metered dose inhaler as defined in claim 17 wherein the stabilizer is selected from the group consisting of the twenty existing amino acids any mixture of any of the foregoing, and any derivative of the foregoing.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17798700P | 2000-01-25 | 2000-01-25 | |
US60/177,987 | 2000-01-25 | ||
US09/702,195 US6585957B1 (en) | 2000-01-25 | 2000-10-30 | Medicinal aerosol formulation |
US09/702,195 | 2000-10-30 | ||
PCT/US2001/000117 WO2001060420A1 (en) | 2000-01-25 | 2001-01-02 | A medicinal aerosol formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2396796A1 true CA2396796A1 (en) | 2001-08-23 |
CA2396796C CA2396796C (en) | 2011-06-21 |
Family
ID=26873842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2396796A Expired - Fee Related CA2396796C (en) | 2000-01-25 | 2001-01-02 | Stabilized medicinal aerosol particulate formulations |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1292283A4 (en) |
JP (1) | JP2003524646A (en) |
CN (1) | CN1440298A (en) |
AU (1) | AU783120B2 (en) |
CA (1) | CA2396796C (en) |
MX (1) | MXPA02007187A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4707327B2 (en) * | 2004-01-27 | 2011-06-22 | 旭化成ファーマ株式会社 | Polypeptides adsorption inhibitors |
ES2281222B1 (en) * | 2004-09-24 | 2008-06-01 | Grifols, S.A. | USE OF ALFA-1 ANTITRIPSIN FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FIBROMIALGIA. |
EP2086642B1 (en) | 2006-10-18 | 2014-06-25 | Periness Ltd. | Dnase for the treatment of male sub-fertility |
SG11201607688YA (en) * | 2014-04-03 | 2016-10-28 | Csl Behring Ag | Nebulization of immunoglobulin |
CN104162142A (en) * | 2014-08-29 | 2014-11-26 | 宁波市微循环与莨菪类药研究所 | Application of N-acetyl aspartoyl glutamic acid dipeptide preparation in treatment of heroin addiction |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3779221D1 (en) * | 1986-08-19 | 1992-06-25 | Genentech Inc | DEVICE AND DISPERSION FOR THE INTRAPULMONAL ENTERING OF POLYPEPTIDE GROWTH SUBSTANCES AND CYTOKINS. |
AU679511B2 (en) * | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
EP1462096B1 (en) * | 1994-03-07 | 2008-12-10 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
SK11142002A3 (en) * | 1999-12-30 | 2004-09-08 | Chiron Corporation | Pharmaceutical composition for interleukine-2 administration and stabilized freeze-dried or spray-dried pharmaceutical composition containing interleukine-2 |
-
2001
- 2001-01-02 CA CA2396796A patent/CA2396796C/en not_active Expired - Fee Related
- 2001-01-02 MX MXPA02007187A patent/MXPA02007187A/en active IP Right Grant
- 2001-01-02 CN CN01807195A patent/CN1440298A/en active Pending
- 2001-01-02 EP EP01901681A patent/EP1292283A4/en not_active Withdrawn
- 2001-01-02 JP JP2001559515A patent/JP2003524646A/en active Pending
- 2001-01-02 AU AU27559/01A patent/AU783120B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
MXPA02007187A (en) | 2002-12-09 |
JP2003524646A (en) | 2003-08-19 |
EP1292283A1 (en) | 2003-03-19 |
EP1292283A4 (en) | 2003-03-19 |
CA2396796C (en) | 2011-06-21 |
AU783120B2 (en) | 2005-09-29 |
CN1440298A (en) | 2003-09-03 |
AU2755901A (en) | 2001-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002255541B2 (en) | Modulated release particles for aerosol delivery | |
US6585957B1 (en) | Medicinal aerosol formulation | |
AU2002243947B2 (en) | Modulated release particles for aerosol delivery | |
AU2002245410B2 (en) | Modulated release particles for aerosol delivery | |
US6596261B1 (en) | Method of administering a medicinal aerosol formulation | |
AU2002255541A1 (en) | Modulated release particles for aerosol delivery | |
AU2002243947A1 (en) | Modulated release particles for aerosol delivery | |
AU2002306462B2 (en) | Modulated release particles for aerosol delivery | |
AU2002245410A1 (en) | Modulated release particles for aerosol delivery | |
US6669959B1 (en) | Modulated release particles for lung delivery | |
AU2002306462A1 (en) | Modulated release particles for aerosol delivery | |
CA2396796A1 (en) | Stabilized medicinal aerosol particulate formulations | |
CA2419077C (en) | A method of treating a systemic disease | |
WO2002005785A1 (en) | Modulated release therapeutic aerosols | |
US20040042966A1 (en) | Method of treating a systemic disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130102 |